CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 826 enrolled
Drug / intervention
Clopidogrel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02983214
NCT02983214Phase 4Completed
CompareCT.gov

Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.

University of Ioannina·interventional·Posted Dec 6, 2016·Updated Dec 29, 2020

In Brief

A Phase 4 clinical trial evaluating Clopidogrel and Cilostazol for Ischemic Stroke and 2 related conditions. Completed, enrolled 826 participants across 1 site.

Detailed Summary

Investigation of the clinical efficacy and safety of dual antiplatelet therapy with clopidogrel and cilostazol versus clopidogrel alone in preventing ischemic vascular events in patients with type 2 diabetes and symptomatic peripheral arterial disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke, Peripheral Artery Disease, Diabetes Mellitus, Type 2
CountriesGreece
CollaboratorsLIBYTEC Pharmaceutical S.A.

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 6, 2016
Enrollment StartNov 1, 2016
Primary CompletionOct 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 9.6 years ago

Interventions

Clopidogreldrug

Cilostazoldrug